鼻内局部利多卡因并非蝶腭神经节阻滞
作者综述解剖学研究及CT和MRI报告,指出局部麻醉药需穿越4-12毫米脂肪和结缔组织才能到达蝶腭神经节,认为该假设不成立。未来研究应关注评估确认蝶腭神经节阻滞的临床生物标志物,如局部脑血流量或泪腺分泌。
要点
- 鼻内局部麻醉药需穿越4-12毫米脂肪和结缔组织才能到达蝶腭神经节。
- 解剖学及影像学证据不支持鼻内局部麻醉药可自由进入翼腭窝。
- 未来研究应评估确认蝶腭神经节阻滞的临床生物标志物。
核心结论
- 鼻内局部利多卡因并非蝶腭神经节阻滞,历史概念不成立。
研究设计与样本
- 本文为叙述性论述,综述解剖学研究及CT和MRI报告。
主要发现
- 局部麻醉药需穿越4-12毫米脂肪和结缔组织才能到达蝶腭神经节。
- 鼻内局部麻醉药无法以足够浓度和体积有效诱导蝶腭神经节阻滞。
临床怎么用
- 不应将鼻内局部利多卡因视为有效的蝶腭神经节阻滞方法。
- 未来临床研究应评估局部脑血流量或泪腺分泌等生物标志物以确认阻滞效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is renewed interest in the central role of the sphenopalatine ganglion (SPG) in cerebrovascular autonomic physiology and the pathophysiology of different primary and secondary headache disorders. There are diverse neural structures (parasympathetic, sympathetic and trigeminal sensory) that convene into the SPG which is located within the pterygopalatine fossa (PPF). This makes the PPF an attractive target to neuromodulatory interventions of these different neural structures. Some experts advocate for the nasal application of local anesthetics as an effective route for SPG block with the belief that the local anesthetic can freely access the PPF. It is time to challenge this historical concept from the early 1900s. In this daring discourse, I will review anatomical studies, CT and MRI reports to debunk this old myth. Will provide anatomical evidence to explain that all these assumptions are untrue and the local anesthetic has to magically 'travel' a distance of 4-12 mm of adipose and connective tissue to reach the SPG in sufficient concentration and volume to effectively induce SPG blockade. Future research should focus on assessing a clinical biomarker to confirm SPG blockade. It could be regional cerebral blood flow or lacrimal gland secretion.
引用
- Narouze S. Topical intranasal lidocaine is not a sphenopalatine ganglion block. Reg Anesth Pain Med. 2020. PMID: 33323391. doi:10.1136/rapm-2020-102173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。